Abstract 453P
Background
Obesity is a risk factor for the development of new cases of breast cancer and also affects survival in women who have already been diagnosed with breast cancer, but in Asian women, these findings is not evident. We aimed to investigate the correlation between the body mass index (BMI) and overall survival of patients with a breast cancer.
Methods
We conducted a retrospective observational study from a single institute from January 2014 to December 2018. Among all 412 patients diagnosed and treated with breast cancer, we categorized them as three groups (low weight: BMI < 18kg/m2, normal: BMI < 25kg/m2, obesity: BMI ≥25kg/m2) and investigated overall survival according to menopausal status and adjuvant endocrine therapy. We used a kaplan-meier analysis with log-rank test.
Results
Total 412 patients were enrolled. Mean duration of follow up was 33.3 months. Obesity, normal BMI and low BMI was 120(29.1%), 202(49.0%), and 40 (9.7%) patients, respectively. BMI was correlated with age, patients with obesity was 16% (28/174) of women with less than 50 years, but 38.6% (92/238) of women with more than 50 years. Overall survival was not significantly different among groups (Obesity group: 95%, Normal group: 95.5%, low BMI: 97.5%, p = 0.77, χ2=1.1). Women without adjuvant hormone therapy show lower overall survival, but it is not significant (Obesity group: 87.7%, Normal group: 94.4%, low BMI: 90%, p = 0.89, χ2=0.62). In women with more than 50 years, low BMI was better than normal to obese women (p = 0.89, χ2=0.6).
Conclusions
Obesity is not major risk factor of overall survival in Korea, but in hormone receptor negative breast cancers, it correlated with early onset death or recurrence. Not only further studies need to lighten the relationship between obesity and long-term survival, but also intervention to reduce BMI needs to know its effects on breast cancer survival in Korea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
220P - An outcome analysis of robotassisted radical nephroureterectomy with extended template lymphadenectomy for upper tract urothelial carcinoma
Presenter: Ashwin Tamhankar
Session: Poster display session
Resources:
Abstract
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract